Sander van Deventer, VectorY & Forbion | Pioneering gene therapy | E11

We’re in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and what’s missing in gene therapy.
💎 ABOUT THE SPEAKER
Sander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the leading VC Forbion as well as Dezima. He is now building a new venture VectorY, again in gene therapy. I interviewed him in 2017 back at Labiotech so it’s great to catch up with him again.

Top 50 Investors in Biotech in 2026: Europe’s Most Active Life Sciences Funds: flot.bio/european-biotech-investors-2026
📜 TRANSCRIPT
Read the full transcript here: flot.bio/episode/sander-van-deventer-gene-ther…
🫶 FOLLOW US

• Newsletter: eepurl.com/h_fnmH
• LinkedIn: linkedin.com/company/flot-bio
• X (Twitter): x.com/FlotBio
🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 10k monthly views. Free.
⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!
🙏 LIKE/FOLLOW/REVIEWDid you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.
⏰ TIMESTAMPS
• [00:00:00] Intro
• [00:01:54] VectorY: Raising the largest Series A in 2023 in 🇪🇺
• [00:05:01] What's coming for ALS
• [00:07:50] How Vectorized Antibodies work
• [00:17:57] New Vector (AAV) technologies
• [00:22:55] The pipeline of VectorY
• [00:27:22] Where VC money is moving to
• [00:32:29] The Netherlands as a biotech cluster
• [00:35:31] CRISPR approval and gene therapy reimbursement
• [00:48:15] Where Sander came from
• [00:56:14] How to have the energy to be a serial entrepreneur